Histopathology of Urological Cancers
Deadline for manuscript submissions: 30 September 2024 | Viewed by 612
Interests: tissue diagnosis of urologic malignancies (prostate cancer; kidney cancer; testis cancer; bladder cancer); immunophenotypic and molecular genetic markers of urologic malignancies
Interests: prostate cancer; molecular genetics and biomarkers; genitourinary malignancies
There has been a tremendous advancement in the diagnosis and management of urologic malignancies. With the release of the 2022 WHO classification of Genito-urinary tumors, several new entities have been described with differences in clinical outcomes. Many new diagnostic criteria have been described that correlate with underlying molecular abnormalities.
To predict prognosis and treatment response, biomarkers have been largely investigated for tissue, urine and blood. The most studied biomarkers include cell cycle, cell signaling, cell adhesion and inflammatory biomarkers. Although promising, a standardized approach and a consensus are still lacking.
The recent development of new therapeutic strategies, such as antibody–drug conjugates (ADCs), monoclonal antibodies targeting a specific cell surface antigen (nectin-4, TROP2 and HER2) and anti-PD-1 agents, has stimulated additional investigations of molecular targets.
In this setting, further research is needed to better stratify patient risk, predict treatment efficacy and assess targeted therapeutic approaches.
This Special Issue aims to collect the most recent developments in histopathologic criteria for the diagnosis of various urologic malignancies and advances in tumor biomarkers with prognostic and predictive value among these tumors. At the same time, this Special Issue will also focus on the usefulness of AI-augmented diagnoses for this group of malignancies. This Special Issue will also collect recent advances in promising or novel therapeutic targets for local treatment or systemic therapy in the entire spectrum of tumors of the urological tract, including retrospective and prospective results from clinical trials or small mono-institutional series.
Authors are encouraged to submit original research articles, review articles and meta-analysis articles.
Dr. Vikas Mehta
Dr. Antoun Toubaji
Dr. Vijayalakshmi Ananthanarayanan
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- renal cell carcinoma
- testis Ggrm cell tumors
- urothelial carcinoma
- artificial intelligence
- ductal adenocarcinoma of prostate
- neuroendocrine differentiation of prostate carcinoma
- next-generation sequencing